261
Participants
Start Date
June 24, 2019
Primary Completion Date
March 4, 2021
Study Completion Date
November 6, 2023
Nivolumab
Specified dose on specified days
Local Institution - 0022, Santiago
Local Institution - 0004, Christchurch
Local Institution - 0005, Auckland
Local Institution - 0046, Buenos Aires
Local Institution - 0001, Wollstonecraft
Local Institution - 0003, Wellington
Local Institution - 0009, Marseille
Local Institution - 0034, Tlalpan
Local Institution - 0043, Pittsburgh
Local Institution - 0014, Bergamo
Local Institution - 0026, Madrid
Local Institution - 0027, Madrid
Local Institution - 0035, Charlotte
Local Institution - 0028, Málaga
Local Institution - 0015, Padua
Local Institution - 0010, Nantes
Local Institution - 0016, Siena
Local Institution - 0008, Minneapolis
Local Institution - 0033, Monterrey
Local Institution - 0031, San Pedro Garza García
Local Institution - 0011, Paris
Local Institution - 0030, Timișoara
Local Institution - 0045, Santiago
Local Institution - 0040, São José do Rio Preto
Local Institution - 0006, Hartford
Local Institution - 0036, Ijuí
Local Institution - 0037, Porto Alegre
Local Institution - 0039, Barretos
Local Institution - 0038, Cerqueira César
Local Institution - 0041, Rio de Janeiro
Local Institution - 0013, Edmonton
Local Institution - 0024, Independencia
Local Institution - 0023, Santiago
Local Institution - 0032, Dublin
Local Institution - 0018, Wilton
Local Institution - 0017, Warsaw
Local Institution - 0029, Badalona-barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY